Modality
Radioligand
MOA
BTKi
Target
PCSK9
Pathway
Complement
MigraineObesityPNH
Development Pipeline
Preclinical
~Feb 2021
→ ~May 2022
Phase 1
Aug 2022
→ Aug 2028
Phase 1Current
NCT04273249
2,259 pts·Obesity
2022-08→TBD·Active
NCT06879043
1,508 pts·PNH
2022-08→2028-08·Terminated
3,767 total pts2 indications
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-08-212.4y awayPh2 Data· PNH
Trial Timeline
Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
P1/2
Active
P1/2
Termina…
Catalysts
Ph2 Data
2028-08-21 · 2.4y away
PNH
ActiveTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04273249 | Phase 1/2 | Obesity | Active | 2259 | CR |
| NCT06879043 | Phase 1/2 | PNH | Terminated | 1508 | BodyWt |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Zanusertib | AbbVie | Approved | PCSK9 | |
| AZN-8281 | AstraZeneca | Phase 1 | SHP2 | |
| BMY-3371 | Bristol-Myers Squibb | Phase 3 | WRN | |
| NVO-7872 | Novo Nordisk | NDA/BLA | B7-H3 | |
| NVO-6275 | Novo Nordisk | Phase 1 | SMN2 | |
| Zanumavacamten | GSK | Phase 2/3 | TROP-2 | |
| TAK-2403 | Takeda | Phase 2 | WEE1 | |
| Lisorapivir | Takeda | Preclinical | WRN | |
| GIL-4361 | Gilead Sciences | Preclinical | PCSK9 | |
| REG-2172 | Regeneron | Phase 1/2 | PCSK9 |